



PEGylated Albumin-Based Drug Carriers for the Treatment of Experimental Stroke

Nazeli Zaqaryan¹, Rita Khallouf^{1,2}, Arpi Manukyan¹ , Vahe Atoyan¹, Astghik Tsokolakyan³ , Mkrtich A. Yeranossyan³ , Samvel G. Chailyan¹ and Kristine E. Danielyan^{1,2,*}

¹Department of H. Buniatian Inst. of Biochem., National Academy of Sciences of the Republic of Armenia (NAS RA), Yerevan 0014, Armenia

²Department of Pharmacy, Eurasia Int. Univ., Yerevan 0014, Armenia

³Department of A. B. Nalbandyan Inst. of Chemical-Physics, National Academy of Sciences of the Republic of Armenia (NAS RA), Yerevan 0014, Armenia

© 2025 The Author(s). Published by Bentham Open.

This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: <https://creativecommons.org/licenses/by/4.0/legalcode>. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



CrossMark

*Address correspondence to this author at the Department of H. Buniatian Inst. of Biochem., National Academy of Sciences of the Republic of Armenia (NAS RA), Yerevan 0014, Armenia and Department of Pharmacy, Eurasia Int. Univ., Yerevan 0014, Armenia; E-mail: kristine_danielyan@biochem.sci.am

Published: July 14, 2025



Cite as: Zaqaryan N, Khallouf R, Manukyan A, Atoyan V, Tsokolakyan A, Yeranossyan M, Chailyan S, Danielyan K. PEGylated Albumin-Based Drug Carriers for the Treatment of Experimental Stroke. Open Biotechnol J, 2025; 19: e18740707379038. <http://dx.doi.org/10.2174/0118740707379038250617195726>

Send Orders for Reprints to reprints@benthamscience.net




Fig. (S1). Evaluation of the zeta potential of the particles.